-
Research in a tweet
Next phase: the PRI-002 Alzheimer’s drug candidate (#Alzheimer-Wirkstoffkandidat), developed at Jülich, can now demonstrate its therapeutic effect in Alzheimer’s patients.
Research in a tweet
Next phase: the PRI-002 Alzheimer’s drug candidate (#Alzheimer-Wirkstoffkandidat), developed at Jülich, can now demonstrate its therapeutic effect in Alzheimer’s patients.
What’s called the Phase II clinical trial, involving Alzheimer’s patients and scheduled to start in 2022, aims to show that PRI-002 has a positive effect on memory and cognition. Results are expected by 2026 at the latest. The drug candidate developed by Prof. Dieter Willbold (photo) and his team has already demonstrated safety and tolerability in daily use over a four-week period. The Federal Agency for Disruptive Innovation, SPRIND, supports the project.
What’s called the Phase II clinical trial, involving Alzheimer’s patients and scheduled to start in 2022, aims to show that PRI-002 has a positive effect on memory and cognition. Results are expected by 2026 at the latest. The drug candidate developed by Prof. Dieter Willbold (photo) and his team has already demonstrated safety and tolerability in daily use over a four-week period. The Federal Agency for Disruptive Innovation, SPRIND, supports the project.
PHOTO: Forschungszentrum Jülich/Sascha Kreklau